Ignite Creation Date:
2025-12-25 @ 1:33 AM
Ignite Modification Date:
2026-01-23 @ 4:14 PM
Study NCT ID:
NCT07245394
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-11-24
First Post:
2025-09-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015212', 'term': 'Inflammatory Bowel Diseases'}, {'id': 'D003424', 'term': 'Crohn Disease'}, {'id': 'D003093', 'term': 'Colitis, Ulcerative'}], 'ancestors': [{'id': 'D005759', 'term': 'Gastroenteritis'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D003092', 'term': 'Colitis'}, {'id': 'D003108', 'term': 'Colonic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000588857', 'term': 'guselkumab'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 200}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2028-11-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-17', 'studyFirstSubmitDate': '2025-09-17', 'studyFirstSubmitQcDate': '2025-11-17', 'lastUpdatePostDateStruct': {'date': '2025-11-24', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-11-24', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2027-11-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Rate of participants achieving early symptomatic response among those not in symptomatic remission at baseline', 'timeFrame': 'Week 4', 'description': "Early symptomatic response at week 4 among patients who were not in symptomatic remission at baseline is defined as follows:\n\n1. For Crohn's disease: A decrease of 30 percent or more in the average daily stool frequency score (SFS) and/or a decrease of 30 percent or more in the average daily abdominal pain score (APS), with both scores not worse than Baseline.\n2. For ulcerative colitis: A decrease of 2 points or more and a decrease of 30 percent or more from Baseline in the modified partial Mayo score (m-pMS)."}, {'measure': 'Rate of participants achieving biochemical remission', 'timeFrame': 'Week 52', 'description': 'Biochemical remission at among patients with available fecal calprotectin (FCAL) and C-reactive protein (CRP).\n\nBiochemical remission is defined as FCAL ≤250 ug/g AND a CRP ≤5 mg/L among patients with available either an elevated FCAL or CRP at baseline.'}, {'measure': 'Rate of participants achieving biochemical remission', 'timeFrame': 'Week 12', 'description': 'Biochemical remission at among patients with available fecal calprotectin (FCAL) and C-reactive protein (CRP).\n\nBiochemical remission is defined as FCAL ≤250 ug/g AND a CRP ≤5 mg/L among patients with available either an elevated FCAL or CRP at baseline.'}, {'measure': 'Change from baseline in quality of life', 'timeFrame': 'Week 52', 'description': 'Quality of Life (QoL) outcomes will be reported as the change from baseline, using the following assessments:\n\nEuroQoL 5-Dimension 5-Level questionnaire (EQ-5D-5L): This tool evaluates five dimensions of health, each rated on a scale from 1 to 5. Higher scores indicate worse health status.\n\nShort Form Health Survey (SF-36): This questionnaire measures eight health domains, with each domain scored from 0 to 100. Higher scores reflect better health status.'}, {'measure': 'Change from baseline in work productivity', 'timeFrame': 'Week 52', 'description': "Work Productivity outcomes will be reported as the change from baseline, assessed using the Work Productivity and Activity Impairment questionnaires specific to Crohn's disease (WPAI-CD) and ulcerative colitis (WPAI-UC). Scores range from 0 to 100 percent, with higher percentages indicating greater impairment in work and daily activities."}, {'measure': 'Change from baseline in mental health (anxiety)', 'timeFrame': 'Week 52', 'description': 'Mental Health (anxiety) outcomes will be reported as the change from baseline, assessed using the Generalized Anxiety Disorder 7-item Scale (GAD-7): Scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.'}, {'measure': 'Change from baseline in mental health (depression)', 'timeFrame': 'Week 52', 'description': 'Mental Health (depression) outcomes will be reported as the change from baseline, assessed using the Patient Health Questionnaire-9 (PHQ-9): Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.'}, {'measure': 'Change from baseline in fatigue', 'timeFrame': 'Week 52', 'description': 'Fatigue outcomes will be reported as the change from baseline, assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT-F). Scores range from 0 to 52, with higher scores indicating less fatigue and better functioning.'}], 'primaryOutcomes': [{'measure': 'Rate of participants achieving deep remission in IBD patients treated with guselkumab after switching from ustekinumab', 'timeFrame': 'Week 52', 'description': 'Deep remission is defined as both absence of symptomatic worsening and endoscopic remission.\n\nOutcomes will be reported as the proportion of participants achieving deep remission at Week 52.'}, {'measure': 'Rate of participants achieving deep remission, stratified by cohorts', 'timeFrame': 'Week 52', 'description': 'Deep remission is defined as both absence of symptomatic worsening and endoscopic remission.\n\nOutcomes will be reported as the proportion of participants achieving deep remission at Week 52 and stratified by Early Switch Cohort (ESC) and Exhausted Ustekinumab Cohort (EUC).'}], 'secondaryOutcomes': [{'measure': 'Rate of participants with absence of symptomatic worsening', 'timeFrame': 'Week 52', 'description': "Absence of symptomatic worsening defined as the absence of:\n\n1. For Crohn's disease: An increase of 30 percent or more in the average daily stool frequency score (SFS) and/or an increase of 30 percent or more in the average daily abdominal pain score (APS) compared to Baseline.\n2. For ulcerative colitis: An increase of 2 points or more and an increase of 30 percent or more compared to Baaseline in the modified partial Mayo score (m-pMS)."}, {'measure': 'Rate of participants achieving endoscopic remission', 'timeFrame': 'Week 52', 'description': "Endoscopic remission is defined as follows:\n\n1. For Crohn's disease: A Simple Endoscopic Score for Crohn's Disease (SDS-CD) of 4 or less, or a score of 2 or less in the ileal segment (excluding the narrowing component) in cases of disease limited to the ileum, with an ulceration subscore of 0.\n2. For ulcerative colitis: A Mayo endoscopic subscore of 1 or less in all segments of the colon."}, {'measure': 'Rate of participants achieving endoscopic response', 'timeFrame': 'Week 52', 'description': "Endoscopic response is defined as follows:\n\n1. For Crohn's disease: A reduction of 50 percent or more in the Simple Endoscopic Score for Crohn's Disease (SDS-CD) compared to Baseline (excluding the narrowing component).\n2. For ulcerative colitis: A decrease of 1 point or more in the Mayo endoscopic subscore compared to Baseline."}, {'measure': 'Rate of participants with absence of symptomatic worsening', 'timeFrame': 'Any study visit (Week 4, Week 12, Week 32, Week 52)', 'description': "Absence of symptomatic worsening defined as the absence of:\n\n1. For Crohn's disease: An increase of 30 percent or more in the average daily stool frequency score (SFS) and/or an increase of 30 percent or more in the average daily abdominal pain score (APS) compared to the baseline value.\n2. For ulcerative colitis: An increase of 2 points or more and an increase of 30 percent or more compared to the baseline value in the modified partial Mayo score (m-pMS)."}, {'measure': 'Rate of participants achieving symptomatic remission among those not in remission at baseline', 'timeFrame': 'Week 12 and Week 52'}, {'measure': 'Rate of participants achieving steroid-free remission among corticosteroid users at baseline', 'timeFrame': 'Week 52', 'description': 'Steroid-free remission defined as no corticosteroid use and meeting symptomatic remission criteria'}, {'measure': 'Rate of participants discontinuing guselkumab therapy', 'timeFrame': 'Any study visit (Week 4, Week 12, Week 32, Week 52)'}]}, 'conditionsModule': {'conditions': ['Inflammatory Bowel Disease (IBD)', 'Crohn Disease (CD)', 'Ulcerative Colitis (UC)', 'IBD-unclassified (IBD-U)']}, 'descriptionModule': {'briefSummary': "The SHIFT-IBD Study is being conducted at multiple medical centers across Canada to evaluate how well guselkumab (Tremfya) works for people with inflammatory bowel disease (IBD) who haven't responded well enough to ustekinumab.\n\nPatients will begin guselkumab based on their doctor's decision. If eligible, they may be invited to participate in the study, which involves monitoring symptoms, test results, and overall health over the course of one year.\n\nGuselkumab will be given according to local medical guidelines. Doctors can adjust the treatment as needed, just like in routine care.\n\nResearchers believe that switching to guselkumab may be as effective as other advanced treatments. For those who saw some improvement on ustekinumab but not enough, guselkumab may offer better symptom control-without worsening results on medical tests like endoscopy.\n\nThe goal is to explore better treatment options for people whose IBD has not been well controlled with current therapies."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'IBD patients who had inadequate response to ustekinumab and switched therapy to guselkumab.', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Subjects of any gender aged ≥ 18.\n* Confirmed diagnosis of IBD (CD, UC, or IBDU) for at least 6 months prior to baseline visit. Subjects with IBDU will be grouped with subjects with UC. The CD proportion of patients will be capped at 75%.\n* Subjects have received ustekinumab for at least 14 weeks and who are currently on or recently discontinued ustekinumab therapy.\n* For subjects that have recently discontinued ustekinumab, the last dose of ustekinumab must have been within 12 weeks before Week 0, and no other advanced therapy (i.e., infliximab, adalimumab, golimumab, certolizumab pegol, vedolizumab, natalizumab, risankizumab, mirikizumab, tofacitinib, upadacitinib, ozanimod, etrasimod) was started since stopping ustekinumab.\n* Subjects with an inadequate response to ustekinumab who require a change in advanced therapy and are initiating guselkumab, as determined by the treating physician.\n* For subjects on off-label ustekinumab dosing (90 mg every 4 or 6 weeks (off-label dosing), enrollment will be capped at 60%.\n* Ability and willingness to give written informed consent and comply with the requirements of this study protocol.\n* Subjects who have evidence of ongoing endoscopic evidence of disease activity within 3 months prior to Week 0, defined as:\n\n * For Crohn's Disease: Colonoscopy showing SES-CD score (excluding the presence of narrowing component) of \\>6 (or \\>4 for participants with isolated ileal disease), OR presence of ulcers larger than 5 mm in any segment.\n * For Ulcerative Colitis: Colonoscopy showing Mayo endoscopic subscore ≥2 in any segment, OR presence of erosions or ulcers in any segment.\n\nExclusion Criteria:\n\n* History of prior exposure to any anti-p19 inhibitor (risankizumab or mirikizumab).\n* Subjects with formal contraindication to guselkumab per the drug label.\n* Use of guselkumab for an off-label indication, dosing regimen, or route of administration. Subjects who did not receive guselkumab induction will be excluded.\n* Subjects with an ostomy or ileo-anal pouch.\n* Subjects with a history of bowel surgery within 6 months prior to Week 0.\n* Subjects displaying clinical signs of acute severe UC, fulminant colitis or toxic megacolon within 3 months prior to Week 0.\n* Subjects who are expected to require bowel surgery by their IBD physician within the year of enrollment.\n* Subjects on 1 or more concomitant biologics.\n* Subjects with a history of colonic dysplasia (low-grade dysplasia, high-grade dysplasia, or colorectal cancer). Note: Patients with a history of indefinite for dysplasia would be eligible.\n* Subjects with formal contraindication or unwilling to undergo lower endoscopy.\n* The patient is considered by the Investigator, for any reason, to be an unsuitable candidate for the study."}, 'identificationModule': {'nctId': 'NCT07245394', 'acronym': 'SHIFT-IBD', 'briefTitle': 'Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)', 'organization': {'class': 'OTHER', 'fullName': 'TIDHI Innovation Inc.'}, 'officialTitle': 'SHIFT-IBD: Switching to High-efficacy Anti-IL-23 Guselkumab in Ustekinumab-exposed Persons With Active IBD', 'orgStudyIdInfo': {'id': 'TIDHI_001'}, 'secondaryIdInfos': [{'id': 'ISRCTN13202059', 'type': 'REGISTRY', 'domain': 'ISRCTN Registry'}]}, 'armsInterventionsModule': {'armGroups': [{'label': 'Early Switch Cohort (ESC)', 'description': 'Patients with CD or UC who had inadequate response to on-label maintenance ustekinumab (90 mg every 8 weeks) that requires a change in advanced therapy, as determined by the treating physician. Inadequate response could be either loss of response, partial response, or persistent endoscopic activity.', 'interventionNames': ['Biological: Guselkumab (Tremfya)']}, {'label': 'Exhausted Ustekinumab Cohort (EUC)', 'description': 'Patients with CD or UC who had inadequate response to off-label maintenance ustekinumab (90 mg every 6 or 4 weeks) that requires a change in advanced therapy, as determined by the treating physician. Inadequate response could be either loss of response, partial response, or persistent endoscopic activity.', 'interventionNames': ['Biological: Guselkumab (Tremfya)']}], 'interventions': [{'name': 'Guselkumab (Tremfya)', 'type': 'BIOLOGICAL', 'description': 'Switching to Guselkumab (Tremfya) in People With Active IBD Previously Treated With Ustekinumab.', 'armGroupLabels': ['Early Switch Cohort (ESC)', 'Exhausted Ustekinumab Cohort (EUC)']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'M6A3B4', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'contacts': [{'name': 'Ajani Jeyakumar, HBSc BScN RN', 'role': 'CONTACT', 'email': 'ajeyakumar@tidhi.ca', 'phone': '6478122113'}], 'facility': 'Toronto Immune and Digestive Health Institute', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}], 'centralContacts': [{'name': 'Ajani Jeyakumar, HBSc BScN RN', 'role': 'CONTACT', 'email': 'ajeyakumar@tidhi.ca', 'phone': '647-812-2113'}, {'name': 'Katy Staikin, MSc', 'role': 'CONTACT', 'email': 'kstaikin@tidhi.ca', 'phone': '647-812-2113'}], 'overallOfficials': [{'name': 'Laura E. Targownik, MD, MSHS, FRCPC', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'TIDHI Innovation Inc.'}, {'name': 'Mark Silverberg, MD, PhD, FRCPC', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'TIDHI Innovation Inc.'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'TIDHI Innovation Inc.', 'class': 'OTHER'}, 'collaborators': [{'name': 'Janssen Inc.', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}